Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin.
In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week. All strains displayed an in vitro sensitivity to the drug. Complete clinical resolution was obtained in 8 patients and long-term eradication in 3. No adverse reactions and only minor and reversible laboratory changes were recorded. Ciprofloxacin could be a valuable oral drug in the treatment of severe urinary infections. However, more clinical studies on the development of resistance under therapy and with other dose schedules are indicated.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001437:Bacteriuria / Q000382:microbiology; D002939:Ciprofloxacin; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011549:Pseudomonas / Q000302:isolation & purification; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011804:Quinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D011804:Quinolines; D002939:Ciprofloxacin